🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07154173
Recruiting Observational

Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer

NCT07154173 · tracked via the Priya Life Science China tracker
Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Phase
Observational
Started
2025-01-01
Last updated
2025-12-31

Condition(s) studied

Rectal NeoplasmsColon NeoplasmsMicrobiotaMetagenome

Investigational drug(s) / intervention(s)

Biospecimen Collection Procedure

Biospecimen Collection Procedure: Collection of fecal samples from healthy volunteers, non-metastatic (M0) and metastatic (M1) colorectal cancer patients. Additionally, collection of tissue samples during surgery from operable patients (M0 and M1) for subsequent research analysis.

Study summary

Colorectal cancer (CRC) is one of the most common and deadly cancers worldwide. About 1 in 4 people with CRC already have cancer spread (metastasis) when first diagnosed, and about half develop spread during their illness. Recent research shows that bacteria living in the gut and even within tumors might play an important role in how cancer spreads.

The goal of this study is to better understand how bacteria might influence the spread of colorectal cancer. The main questions the investigators aim to answer are:

Are there differences in bacteria between people whose cancer has spread and those whose cancer has not spread? Could certain bacteria help predict which cancers might spread?

To answer these questions, the investigators will:

Collect different types of samples from participants:

Tumor tissue Normal tissue near the tumor Tissue from where cancer has spread Stool samples before surgery Study the bacteria in these samples using advanced testing methods Compare bacterial patterns between different groups

People can take part in this study if they:

Are between 18 and 75 years old Have colorectal cancer confirmed by doctors Have not taken antibiotics recently Do not have immune system problems

This research may help us:

Understand why some colorectal cancers spread Find new ways to predict which cancers might spread Develop better treatments for colorectal cancer

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age between 18 and 75 years * Pathologically confirmed colorectal cancer * Clearly defined clinical staging: including imaging or pathologically confirmed metastatic colorectal cancer (stage M1) and colorectal cancer without distant metastasis (stage M0) * Expected survival ≥ 3 months * Voluntary participation and signed informed consent Exclusion Criteria: * Use of probiotics, antibiotics, or immunosuppressive agents within 1 month before surgery * Preoperative complete intestinal obstruction or gastrointestinal perforation * Intraoperative gastrointestinal perforation or tumor rupture * Previous history of gastrointestinal surgery (excluding colorectal cancer surgery, appendectomy, and cholecystectomy) or concurrent severe gastrointestinal diseases such as inflammatory bowel disease * Concurrent active systemic immune or infectious diseases, including severe allergies, rheumatoid arthritis, systemic lupus erythematosus, viral hepatitis, acquired immunodeficiency syndrome, etc. * Concurrent unhealed primary malignant tumors * Severe organ dysfunction or failure * Other conditions deemed unsuitable for this study by the investigator

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Sixth Affiliated Hospital of Sun Yat-sen University Guangzhou Guangdong Recruiting

More Sixth Affiliated Hospital, Sun Yat-sen University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07154173 on ClinicalTrials.gov ↗ ← All trials in China